82 related articles for article (PubMed ID: 16257855)
1. Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics.
Gaudreault J; Shiu V; Bricarello A; Christian BJ; Zuch CL; Mounho B
Int J Toxicol; 2005; 24(5):357-63. PubMed ID: 16257855
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K
Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
[TBL] [Abstract][Full Text] [Related]
3. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Kabbinavar FF; Schulz J; McCleod M; Patel T; Hamm JT; Hecht JR; Mass R; Perrou B; Nelson B; Novotny WF
J Clin Oncol; 2005 Jun; 23(16):3697-705. PubMed ID: 15738537
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Kabbinavar FF; Wallace JF; Holmgren E; Yi J; Cella D; Yost KJ; Hurwitz HI
Oncologist; 2008 Sep; 13(9):1021-9. PubMed ID: 18776057
[TBL] [Abstract][Full Text] [Related]
6. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
Fujishima H; Kikuchi I; Miyanaga O; Ueda A; Baba E; Mitsugi K; Harada M; Nakano S
Int J Clin Oncol; 2004 Apr; 9(2):92-7. PubMed ID: 15108040
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Messersmith WA; Laheru DA; Senzer NN; Donehower RC; Grouleff P; Rogers T; Kelley SK; Ramies DA; Lum BL; Hidalgo M
Clin Cancer Res; 2004 Oct; 10(19):6522-7. PubMed ID: 15475439
[TBL] [Abstract][Full Text] [Related]
9. Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.
Horita Y; Yamada Y; Hirashima Y; Kato K; Nakajima T; Hamaguchi T; Shimada Y
Cancer Chemother Pharmacol; 2010 Feb; 65(3):467-71. PubMed ID: 19554330
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.
Graeven U; Ridwelski K; Artandi M; Espana P; Schölmerich J; Rosales AM; Carlsson G; Borner M; Boussard B; Schmiegel W
Oncol Rep; 2005 Apr; 13(4):681-8. PubMed ID: 15756442
[TBL] [Abstract][Full Text] [Related]
11. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
Denlinger CS; Blanchard R; Xu L; Bernaards C; Litwin S; Spittle C; Berg DJ; McLaughlin S; Redlinger M; Dorr A; Hambleton J; Holden S; Kearns A; Kenkare-Mitra S; Lum B; Meropol NJ; O'Dwyer PJ
Cancer Chemother Pharmacol; 2009 Dec; 65(1):97-105. PubMed ID: 19415281
[TBL] [Abstract][Full Text] [Related]
13. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
Budai B; Nagy T; Láng I; Hitre E
Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
Kummar S; Copur MS; Rose M; Wadler S; Stephenson J; O'Rourke M; Brenckman W; Tilton R; Liu SH; Jiang Z; Su T; Cheng YC; Chu E
Clin Colorectal Cancer; 2011 Jun; 10(2):85-96. PubMed ID: 21859559
[TBL] [Abstract][Full Text] [Related]
15. The role of bevacizumab as first-line therapy for colon cancer.
Marshall J
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S43-7. PubMed ID: 16399431
[TBL] [Abstract][Full Text] [Related]
16. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
Kabbinavar F; Hurwitz HI; Fehrenbacher L; Meropol NJ; Novotny WF; Lieberman G; Griffing S; Bergsland E
J Clin Oncol; 2003 Jan; 21(1):60-5. PubMed ID: 12506171
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys.
Xu L; Zuch CL; Lin YS; Modi NB; Lum BL
Cancer Chemother Pharmacol; 2008 Apr; 61(4):607-14. PubMed ID: 17549476
[TBL] [Abstract][Full Text] [Related]
19. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
Falcone A; Masi G; Allegrini G; Danesi R; Pfanner E; Brunetti IM; Di Paolo A; Cupini S; Del Tacca M; Conte P
J Clin Oncol; 2002 Oct; 20(19):4006-14. PubMed ID: 12351598
[TBL] [Abstract][Full Text] [Related]
20. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
